 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...9596979899100101102103104105...123124» |
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] SERUM ST6GAL1 IS A NOVEL BIOMARKER FOR PREDICTING EFFICACY OF TYROSINE KINASE INHIBITORS IN HEPATOCELLULAR CARCINOMA () - Oct 11, 2020 - Abstract #AASLD2020AASLD_164;
Tumor-bearing mice were then treated with lenvatinib (LEN), or sorafenib (SOR), or vehicle until moribund. ST6GAL1 is a tumor-derived secreted protein downstream of FGF19 that may be a useful serum biomarker for identification of patients with FGF19-driven HCC who may benefit from LEN therapy.
- | lenvatinib / Generic mfg.
Journal: Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma. (Pubmed Central) - Oct 9, 2020
Ulcer healing was confirmed after rabeprazole was replaced with vonoprazan and misoprostol. Our case shows that lenvatinib can induce duodenal ulcers resulting in obstructive jaundice.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy: Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials (clinicaltrials.gov) - Oct 9, 2020
P2, N=50, Active, not recruiting, Sponsor: Eisai Inc.
Our case shows that lenvatinib can induce duodenal ulcers resulting in obstructive jaundice. Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1425;
P2
Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT02702388.
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter, randomized, double-blind, placebo (PBO) - controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1420;
P3
and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Clinical trial identification: NCT02966093.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Evaluation of first:line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta:analysis (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1230;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1228;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- lenvatinib / Generic mfg.
[VIRTUAL] Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1227;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1226;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- lenvatinib / Generic mfg.
[VIRTUAL] Effect of adjuvant lenvatinib (LEN) on tumour recurrence in patients with hepatocellular carcinoma (HCC) and high residual alpha:fetoprotein (AFP) following resection or ablation: A single-center, retrospective study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1225;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci
[VIRTUAL] Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1221;
Legal entity responsible for the study: The authors. Funding: National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1220;
P4
Funding: Beijing Hospitals Authority, QML20191805. Clinical trial identification: NCT04127396.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1219;
P2
3207027381; National Natural Science Foundation of China, 81472306; Key research and development program of Jiangsu Province.BE2016789. Clinical trial identification: NCT04052152.
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter, randomized, doubleblind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodinerefractory differentiated thyroid cancer (RRDTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1061;
P2
These data support selection of LEN 24 mg/d as an appropriate starting dose for pts with RR-DTC. Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter, randomized, doubleblind, placebo (PBO)controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodinerefractory differentiated thyroid cancer (RRDTC) in China (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1056;
P3
Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- [VIRTUAL] A multicenter, openlabel, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC082) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_955;
P2
All AEs will be recorded. Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Evaluation of firstline systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network metaanalysis (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_865;
This NMA suggested that greater ORR and TTP benefits with first-line use of Lenvatinib than others. Although Atezolizumab+Bevacizumab showed more benefit in PFS, more discontinuation because of AE should also take into consideration.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_863;
Regardless of the retrospective nature, the present study as the first up-to-date real-world evidence indicates that Regorafenib combined with TACE was clinically effective and tolerable in subsequent to prior systemic therapy for unresectable HCC. Additional prospective large-scale studies are required to further verify our conclusion.
- lenvatinib / Generic mfg.
[VIRTUAL] Realworld efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_862;
The most common grade 3-4 toxicities were hyperbilirubinemia (n=8, 10.7%), AST elevation (n=6, 8.0%) and diarrhea (n=4, 5.3%). LEN was effective and well tolerated in pts with aHCC in Korean real-life setting.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Organ specific tumour response to firstline (1L) therapy with combined lenvatinib (LEN) and antiPD1 antibodies in patients with unresectable hepatocellular carcinoma (HCC) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_861;
The response of MVTT to combined LEN and anti-PD-1 antibodies was higher versus HCC tumors in other sites. The mechanisms underlying this differential response warrant further investigation.
- lenvatinib / Generic mfg.
[VIRTUAL] Effect of adjuvant lenvatinib (LEN) on tumour recurrence in patients with hepatocellular carcinoma (HCC) and high residual alphafetoprotein (AFP) following resection or ablation: A singlecenter, retrospective study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_860;
LEN led to an AFP response in 61% of patients with HCC and residual elevated AFP post surgery/ablation, and this was associated with a high 1-year RFS. Therefore, AFP response may provide a biomarker to predict response to LEN in this setting and further investigation in prospective trials is warranted.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci
[VIRTUAL] Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_856;
Triple combination therapy of lenvatinib, toripalimab, and HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced HCC. National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_855;
P4
Differences in ORR and OS did not reach statistical significance, which may be due to the limited sample size and requires further study. Beijing Hospitals Authority, QML20191805.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Sintilimab plus anlotinib as firstline therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_854;
P2
LGY2017069; Joint Research Project by Southeast University and Nanjing Medical University. 3207027381; National Natural Science Foundation of China, 81472306; Key research and development program of Jiangsu Province.BE2016789.
- [VIRTUAL] A multicenter, openlabel, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC082) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_712;
P2
All AEs will be recorded. Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter, randomized, doubleblind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodinerefractory differentiated thyroid cancer (RRDTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_695;
P2
These data support selection of LEN 24 mg/d as an appropriate starting dose for pts with RR-DTC. Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter, randomized, doubleblind, placebo (PBO)controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodinerefractory differentiated thyroid cancer (RRDTC) in China (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_690;
P3
Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Evaluation of firstline systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network metaanalysis (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_492;
This NMA suggested that greater ORR and TTP benefits with first-line use of Lenvatinib than others. Although Atezolizumab+Bevacizumab showed more benefit in PFS, more discontinuation because of AE should also take into consideration.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_490;
Regardless of the retrospective nature, the present study as the first up-to-date real-world evidence indicates that Regorafenib combined with TACE was clinically effective and tolerable in subsequent to prior systemic therapy for unresectable HCC. Additional prospective large-scale studies are required to further verify our conclusion.
- lenvatinib / Generic mfg.
[VIRTUAL] Realworld efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_489;
The most common grade 3-4 toxicities were hyperbilirubinemia (n=8, 10.7%), AST elevation (n=6, 8.0%) and diarrhea (n=4, 5.3%). LEN was effective and well tolerated in pts with aHCC in Korean real-life setting.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Organ specific tumour response to firstline (1L) therapy with combined lenvatinib (LEN) and antiPD1 antibodies in patients with unresectable hepatocellular carcinoma (HCC) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_488;
The response of MVTT to combined LEN and anti-PD-1 antibodies was higher versus HCC tumors in other sites. The mechanisms underlying this differential response warrant further investigation.
- lenvatinib / Generic mfg.
[VIRTUAL] Effect of adjuvant lenvatinib (LEN) on tumour recurrence in patients with hepatocellular carcinoma (HCC) and high residual alphafetoprotein (AFP) following resection or ablation: A singlecenter, retrospective study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_487;
LEN led to an AFP response in 61% of patients with HCC and residual elevated AFP post surgery/ablation, and this was associated with a high 1-year RFS. Therefore, AFP response may provide a biomarker to predict response to LEN in this setting and further investigation in prospective trials is warranted.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci
[VIRTUAL] Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_483;
Triple combination therapy of lenvatinib, toripalimab, and HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced HCC. National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_482;
P4
Differences in ORR and OS did not reach statistical significance, which may be due to the limited sample size and requires further study. Beijing Hospitals Authority, QML20191805.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Sintilimab plus anlotinib as firstline therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_481;
P2
LGY2017069; Joint Research Project by Southeast University and Nanjing Medical University. 3207027381; National Natural Science Foundation of China, 81472306; Key research and development program of Jiangsu Province.BE2016789.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
#Lenvatinib #Lenvanix #乐伐替尼 #崙伐替尼 4mg #肝細胞癌（HCC）#腎細胞癌（RCC）#甲狀腺癌（DTC）#Lenvima #E7080 #lenvanat #lenvanix #lenvanib #lucilenva treats #livercancer #thyroidcancer #kidneycancer Thuốc Lenvanix 4mg 10mg Lenvatinib điều trị ung thư gan, thận, tuyến giáp (Twitter) - Oct 8, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. (Pubmed Central) - Oct 7, 2020
Lenvatinib pharmacokinetics were significantly influenced by the CYP3A4*1G polymorphism. If the target plasma concentration of lenvatinib for efficacy or toxicity is determined, elucidation of the details of the CYP3A4*1G genotype may facilitate decision-making related to the appropriate initial lenvatinib dosage to achieve optimal plasma concentrations.
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 7, 2020
P3, N=650, Recruiting, Sponsor: Bristol-Myers Squibb
If the target plasma concentration of lenvatinib for efficacy or toxicity is determined, elucidation of the details of the CYP3A4*1G genotype may facilitate decision-making related to the appropriate initial lenvatinib dosage to achieve optimal plasma concentrations. N=1084 --> 650
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Stroma, Metastases: LENVAGIST: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (clinicaltrials.gov) - Oct 4, 2020
P2, N=74, Recruiting, Sponsor: Centre Leon Berard
N=1084 --> 650 Trial completion date: Oct 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Sep 2022
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Real-World Effectiveness of Lenvatinib in the Patients with Hepatocellular Carcinoma- An Evidence from Taiwan () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_744;
However, the duration of treatment was less than REFLECT trial. Future large-scale studies were suggested to confirm the real-world effectiveness between lenvatinib and sorafenib.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) - Oct 3, 2020
Lenvatinib had potential benefits for patients with advanced HCC with second- or later-line therapies and a high burden of intrahepatic lesions. Dose modification should be paid increased attention among patients with poor liver function, such as Child-Pugh class B patients.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_784;
P2
Lenvatinib in combination with pembrolizumab showed promising antitumor activity with manageable toxicity in patients with previously treated advanced TNBC. Based on these early data, the cohort will be expanded to include 100 patients.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker: Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report. (Pubmed Central) - Oct 2, 2020
We identified a BRCA2 germline mutation in a patient with liver cancer. Our findings could offer an alternative management for patients with liver cancer harboring germline BRCA2 mutation.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Oct 1, 2020
P2, N=40, Recruiting, Sponsor: National University Hospital, Singapore
Our findings could offer an alternative management for patients with liver cancer harboring germline BRCA2 mutation. Trial completion date: Jun 2018 --> Jun 2021 | Trial primary completion date: Jan 2018 --> Jan 2021
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Clinical, Journal: Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial. (Pubmed Central) - Sep 30, 2020
ChiCTR1900027102. October 31, 2019.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? (Pubmed Central) - Sep 30, 2020
We found that TKIs with promising therapeutic effect for osteosarcoma include apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib...It is necessary to inhibit several relevant RTKs simultaneously to achieve a breakthrough in osteosarcoma treatment. This review provides comprehensive information on TKI targets relevant in osteosarcoma treatment, and it will be useful for further research in this field.
- || Avastin (bevacizumab) / Roche
Review, Journal: Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date. (Pubmed Central) - Sep 30, 2020
Indeed, preliminary results from phase I studies of lenvatinib plus pembrolizumab and atezolizumab plus bevacizumab have proved favorable, prompting phase III investigations in the frontline setting, and for atezolizumab plus bevacizumab, these positive findings have been substantiated by recent reporting of phase III data from IMbrave150. In this review, we will present the currently available data on combination therapy atezolizumab plus bevacizumab in advanced HCC, and compare these findings to other promising combination treatments, most notably that of lenvatinib plus pembrolizumab.
- || volrustomig (MEDI5752) / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 29, 2020
P1b, N=52, Recruiting, Sponsor: MedImmune LLC
In this review, we will present the currently available data on combination therapy atezolizumab plus bevacizumab in advanced HCC, and compare these findings to other promising combination treatments, most notably that of lenvatinib plus pembrolizumab. Trial completion date: Mar 2023 --> Mar 2022 | Trial primary completion date: Mar 2023 --> Mar 2022
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC) () - Sep 27, 2020 - Abstract #COSA2020COSA_312;
P1b/2, P3
No new safety signals emerged. A phase 3 study of LEN + PEMBRO for first-line treatment in advanced/recurrent EC is underway (NCT03884101).
- [VIRTUAL] Phase 2 trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): results by independent imaging review and subgroup analyses () - Sep 27, 2020 - Abstract #COSA2020COSA_279;
PEMBRO + axitinib is approved first-line for advanced RCC...No new safety signals were detected. Efficacy by investigator assessment irRECIST N=104 ORR, n/N (%) [95% CI] 57/104 (54.8) [44.7-64.6] Prior anti-PD-1/PD-L1 and anti-VEGF 40/68 (58.8) [46.2-70.6] Prior nivolumab + ipilimumab 18/38 (47.4) [31-64.2] PD-L1 status Positive 22/44 (50) [34.6-65.4] Negative 27/43 (62.8) [46.7-77] ORR(week 24), n (%) [95% CI] 53 (51) [41-60.9] DORa (95% CI) 12.2 (8.5-18.2) Time to responsea (range) 1.6 (1.2-13.7) PFSa (95% CI) 11.7 (9.4-17.7) OSa Not reached aMedian, months